Efficacy, Tolerability and Adverse Events of Single-Shot Intra-Articular Hyaluronic Acid Injection in Knee Osteoarthritis
|Shahid Hussain1*, Hamid Rather1 and Asif Qayoom2|
|1Department of Physical Medicine and Rehabilitation, Sheri-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu & Kashmir, India|
|2Urgent Care Hospital, New Delhi, India|
|Corresponding Author :||Shahid Hussain
Department of Physical Medicine and Rehabilitation
Sheri-Kashmir Institute of Medical Sciences
Soura, Srinagar, Jammu & Kashmir, India
E-mail: [email protected]
|Received April 29, 2015; Accepted June 12, 2015; Published June 18, 2015|
|Citation: Hussain S, Rather H, Qayoom A (2015) Efficacy, Tolerability and Adverse Events of Single-Shot Intra-Articular Hyaluronic Acid Injection in Knee Osteoarthritis. J Trauma Treat 4:256. doi:10.4172/2167-1222.1000256|
|Copyright: © 2015 Hussain S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at Pubmed, Scholar Google|
Objective: The clinical experience with single intra-articular hyaluronic acid injection in knee OA is limited. The aim was to assess the therapeutic efficacy, tolerability and adverse events of single-shot intra-articular hyaluronic acid injection in knee OA.
Method: Between February 2008 and December 2010, forty eight (48) patients (Males=21, Females=27) with OA knees were enrolled in this prospective study. These patients had failed to respond adequately to conservative treatment including analgesics and rehabilitative modalities. The inclusion criteria were: 1) Resting visual analog scale pain of >50 mm and 2) Radiographic evidence for osteoarthritis and at least one of the following three characteristics; Age ≥50 yrs, Morning stiffness ≤ 30 min in duration and coarse crepitus on motion (as per American College of Rheumatology guidelines 1986). Functional scoring as per WOMAC and VAS for pain at rest and during walking was documented. Patient satisfaction was documented as per Linkert scale. Objective analysis included measurement of knee flexion-extension, circumference at the level of suprapatellar pouch and change in joint space width (Tibiofemoral joint). Patients received a single injection of Synvisc-One (consisting of 6 ml hylan G-F 20). The patients were reviewed at 1 month, 3 months and 6 months post-injection with final analysis at 1 year. Use of only paracetamol, when required was allowed for concomitant analgesia but disallowed around the time of clinical evaluation.
Results: The mean age of the patients was 65 ± 5 years; mean duration of symptoms 5.4 ± 1.5 years and mean body mass index (BMI) 29.1 kg/m2. Bilateral knees were involved in 69% of patients. Knee swelling and effusion was present in 70% and 31.5% patients, respectively. All the patients were available at final follow-up. The resting and walking VAS pain significantly improved from baseline after the injection (45 from 70 and 50 from 82, respectively). There was significant improvement of pain and disability based on the WOMAC scores. Adverse events were recorded and included local pain and swelling, mild redness, and/or effusion in the knee. Based on “Knee Society Score” the overall efficacy was judged as excellent in 55%, satisfactory in 43%, and poor in 2%. The beneficial effects stayed till 6 months but returned to baseline at last follow up at 1 year. Substantial improvement was noted in knee flexionextension and knee swelling (p<0.05) but no change was observed in joint space width.
Conclusions: This study confirmed the therapeutic efficacy and safety of single-shot intra-articular injection of hyaluronic acid for the treatment of osteoarthritis of the knee. The pain relief and functional improvement lasts for up to 6 months. The procedure is tolerated well and associated with very few local adverse events. The need for concomitant analgesia is reduced.